The patent number 11,661,405 has been issued by the US Patent and Trademark Office (USPTO) and is expected to remain effective until October 2036.
This expands the company’s patent coverage for certain ANAVEX 2-73 crystal forms preparation methods, compositions, and uses thereof, which are covered by the US patent number 10,413,519.
Anavex’s orally available drug candidate restores cellular homeostasis by targeting sigma-1 and M1 muscarinic receptors.
The company stated that the ANAVEX 2-73 compound in one of its crystal forms was used in several preclinical and clinical trials, for a wide range of CNS disorders, including Rett syndrome, Angelman syndrome, Parkinson’s disease, Fragile X syndrome, Alzheimer’s disease, Parkinson’s disease dementia, Infantile spasms, as well as other undisclosed rare CNS disorders.
The drug candidate has completed a Phase IIa and Phase IIb/III clinical trial for Alzheimer’s disease, a Phase II and a Phase III trial in Rett syndrome adult patients, and a Phase II proof-of-concept trial in Parkinson’s disease.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Anavex Life Sciences president and CEO Christopher Missling said: “This new patent relating to ANAVEX 2-73 is exceptionally important for ANAVEX, because all clinical trials with ANAVEX 2-73 (blarcamesine), including Alzheimer’s disease Phase IIb/III ANAVEX 2-73-AD-004 study are using the patent protected crystal forms as the active pharmaceutical ingredient.
“We are extremely pleased with the continued development of the patent portfolio for ANAVEX 2-73 (blarcamesine) which demonstrates our continued commitment to protecting all aspects of the Anavex product portfolio.”